Kiora Pharmaceuticals
KPRX
16 hedge funds and large institutions have $2.68M invested in Kiora Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
11% less funds holding
Funds holding: 18 → 16 (-2)
12.23% less ownership
Funds ownership: 42.85% → 30.61% (-12%)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
31% less capital invested
Capital invested by funds: $3.87M → $2.68M (-$1.19M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
Top Sellers
KPRX Hedge Fund Activity: Q2 2025 in Review
16 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q2 2025, worth a combined $2.68M — down 31% from $3.87M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of KPRX and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was UBS Group, adding an estimated $53.8K. The largest seller was Rosalind Advisors, exiting entirely with an estimated $753K sold.
- 16 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q2 2025, down from 18 in Q1 2025.
- Funds reported $2.68M of Kiora Pharmaceuticals stock for Q2 2025, down 31% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q2 2025 and 4 closed out, a net change of -2 holders.
- The largest Kiora Pharmaceuticals buyer in Q2 2025 was UBS Group, an estimated $53.8K added.
- The largest Kiora Pharmaceuticals seller in Q2 2025 was Rosalind Advisors, an estimated $753K sold.
Based on aggregated 13F filings for Q2 2025.